# EDGAR Filing Document

**Accession Number:** 0001053691
**File Stem:** 0001437749-25-021278
**Filing Date:** 2025-6
**Character Count:** 8217
**Document Hash:** d6847bd3b353370b7ec06e0d186538c4
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-25-021278.hdr.sgml**: 20250625

**ACCESSION NUMBER**: 0001437749-25-021278

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20250623

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250625

**DATE AS OF CHANGE**: 20250625

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CervoMed Inc.
- **CENTRAL INDEX KEY:** 0001053691
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 300645032
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37942
- **FILM NUMBER:** 251074447

**BUSINESS ADDRESS:**
- **STREET 1:** 20 PARK PLAZA
- **STREET 2:** SUITE 424
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116
- **BUSINESS PHONE:** (617) 744-4400

**MAIL ADDRESS:**
- **STREET 1:** 20 PARK PLAZA
- **STREET 2:** SUITE 424
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02116

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Diffusion Pharmaceuticals Inc.
- **DATE OF NAME CHANGE:** 20160115

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** RestorGenex Corp
- **DATE OF NAME CHANGE:** 20140307

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Stratus Media Group, Inc
- **DATE OF NAME CHANGE:** 20080722

?xml version='1.0' encoding='ASCII'? crvo20250625_8k.htm

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

------

**FORM 8-K**

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of The Securities Exchange Act of 1934**

**June 23, 2025**

**Date of Report (Date of earliest event reported)**

------

## CervoMed Inc.
**(Exact name of registrant as specified in its charter)**

------

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-37942** | **30-0645032** |
| **(State or other jurisdiction**<br> **of incorporation)** | **(Commission**<br> **File Number)** | **(I.R.S. Employer**<br> **Identification No.)** |
| **20 Park Plaza, Suite 424**<br> **Boston, Massachusetts** | **20 Park Plaza, Suite 424**<br> **Boston, Massachusetts** | **02116** |
| **(Address of principal executive offices)** | **(Address of principal executive offices)** | **(Zip Code)** |

---

**Registrant**'**s telephone number, including area code: (617) 744-4400**

**Not applicable**

**(Former name or former address, if changed since last report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br> **Symbol(s)** | **Name of each exchange**<br> **on which registered** |
| Common Stock, $0.001 par value | CRVO | NASDAQ Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 5.07**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Submission of Matters to a Vote of Security Holders**

The 2025 Annual Meeting of Stockholders (the "Annual Meeting") of CervoMed Inc. (the "Company" or "we") was held on June 23, 2025. Stockholders of record at the close of business on April 24, 2025 (the "Record Date"), were entitled to vote at the Annual Meeting and, as of the Record Date, there were 8,702,719 shares of the Company's common stock outstanding. At the Annual Meeting, the holders of 5,610,237 shares were present, virtually or by proxy, representing approximately 64.5% of the shares outstanding as of the Record Date and, accordingly, a quorum was present at the Annual Meeting.

The matters submitted to the Company's stockholders and voted upon at the meeting, which are more fully described in the Company's Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 29, 2025 (the "Proxy Statement"), as well as the results of each such vote were as follows:

(1) Proposal No. 1 – To elect seven persons to serve as directors until the Company's next Annual Meeting of Stockholders or until their respective successors are elected and qualified.

The election of each nominee pursuant to Proposal No. 1 required the affirmative vote of a plurality of the votes present and entitled to vote at the Annual Meeting and, accordingly, each nominee received the requisite number of votes for election at the Annual Meeting.

---

| | | | |
|:---|:---|:---|:---|
| | For | Withheld | Broker Non-Votes |
| John Alam, M.D. | 3923241 | 21554 | 1665442 |
| Joshua S. Boger, Ph.D. | 3928919 | 15876 | 1665442 |
| Sylvie Grégoire, PharmD. | 3924920 | 19875 | 1665442 |
| Jane H. Hollingsworth, J.D. | 3840585 | 104210 | 1665442 |
| Jeff Poulton | 3910346 | 34449 | 1665442 |
| Marwan Sabbagh, M.D. | 3928461 | 16334 | 1665442 |
| Frank Zavrl | 3909962 | 34833 | 1665442 |

---

(2) Proposal No. 2 – To ratify the selection of RSM US LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025.

The approval of Proposal No. 2 required the affirmative vote of a majority of the votes present and entitled to vote at the Annual Meeting and, accordingly, Proposal No. 2 received the requisite number of votes for approval at the Annual Meeting.

---

| | | |
|:---|:---|:---|
| For | Against | Abstain |
| 5571505 | 25008 | 13724 |

---

(3) Proposal No. 3 – To approve, on an advisory basis, the compensation of the Company's named executive officers during the year ended December 31, 2024, as disclosed in the Proxy Statement.

The approval of Proposal No. 3 required the affirmative vote of a majority of the votes present and entitled to vote at the Annual Meeting and, accordingly, Proposal No. 3 received the requisite number of votes for approval at the Annual Meeting.

---

| | | | |
|:---|:---|:---|:---|
| For | Against | Abstain | Broker Non-Votes |
| 3891229 | 33195 | 20371 | 1665442 |

---

(4) Proposal No. 4 – To approve the CervoMed Inc. 2025 Equity Incentive Plan.

The approval of Proposal No. 4 required the affirmative vote of a majority of the votes present and entitled to vote at the Annual Meeting and, accordingly, Proposal No. 4 received the requisite number of votes for approval at the Annual Meeting.

---

| | | | |
|:---|:---|:---|:---|
| For | Against | Abstain | Broker Non-Votes |
| 3798568 | 137758 | 8469 | 1665442 |

---

**Item 9.01**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Financial Statements and Exhibits**

***(d)***&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ***Exhibits***

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: June 25, 2025 | **CervoMed Inc.** | **CervoMed Inc.** |
|  | By: | /s/ William Elder |
|  | Name: | William Elder |
|  | Title: | Chief Financial Officer & General Counsel |

---